These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19786702)

  • 1. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Engel WK
    Neurology; 2009 Sep; 73(13):1077; author reply 1077-8. PubMed ID: 19786702
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Khan OA; Tselis A; Boster A
    Neurology; 2009 Jun; 72(24):2134; author reply 2134-5. PubMed ID: 19528523
    [No Abstract]   [Full Text] [Related]  

  • 4. [Intravenous immunoglobulins for relapsing-remitting multiple sclerosis after failure of treatment with other immuno-modulators].
    Lebrun C; Ghetau G; Bourg V; Chanalet S; Dumas S; Chatel M
    Rev Neurol (Paris); 2003 Jul; 159(6-7 Pt 1):648-51. PubMed ID: 12910072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
    Bayry J; Hartung HP; Kaveri SV
    Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.
    Haas J; Hommes OR
    Mult Scler; 2007 Aug; 13(7):900-8. PubMed ID: 17881400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].
    Brassat D
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1014-28. PubMed ID: 11787332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose, frequently administered interferon beta.
    Limmroth V; Putzki N
    J Neurol Sci; 2005 Apr; 231(1-2):95-6; author reply 97-9. PubMed ID: 15792828
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinsonism as a manifestation of multiple sclerosis.
    Folgar S; Gatto EM; Raina G; Micheli F
    Mov Disord; 2003 Jan; 18(1):108-10. PubMed ID: 12518309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interrupted immunomodulant therapy on the neurological state of multiple sclerosis patients.
    Bencsik K; Fricska-Nagy Z; Rajda C; Füvesi J; Török M; Vécsei L; Csépány T; Mátyás K; Dobos E; Rózsa C; Semjén J
    J Neurol Sci; 2007 Sep; 260(1-2):296-7. PubMed ID: 17475280
    [No Abstract]   [Full Text] [Related]  

  • 11. Breastfeeding and multiple sclerosis in a German cohort.
    Hellwig K; Gold R
    Mult Scler; 2008 Jun; 14(5):718. PubMed ID: 18566037
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab in relapsing-remitting multiple sclerosis.
    Chaudhuri A; Behan PO
    N Engl J Med; 2008 Jun; 358(24):2646; author reply 2646-7. PubMed ID: 18557178
    [No Abstract]   [Full Text] [Related]  

  • 13. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
    Cursiefen S; Flachenecker P; Toyka KV; Rieckmann P
    Eur Neurol; 2000; 43(3):186-7. PubMed ID: 10765063
    [No Abstract]   [Full Text] [Related]  

  • 14. [High dosage corticosteroids: in multiple sclerosis pulse therapy is of value].
    Gold R
    MMW Fortschr Med; 1999 Jun; 141(25):76-7. PubMed ID: 10897917
    [No Abstract]   [Full Text] [Related]  

  • 15. The levels of C3 and C4 components of the complement in the sera of relapsing-remitting multiple sclerosis patients (RR-MS) treated by 2-CDA (cladribine).
    Bartosik-Psujek H; Stelmasiak Z; Mitosek-Szewczyk K; Belniak-Legieć E; Dobosz B
    Ann Univ Mariae Curie Sklodowska Med; 2000; 55():231-4. PubMed ID: 11482079
    [No Abstract]   [Full Text] [Related]  

  • 16. Relapse management in multiple sclerosis.
    Thrower BW
    Neurologist; 2009 Jan; 15(1):1-5. PubMed ID: 19131851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update].
    Stangel M; Gold R
    Nervenarzt; 2005 Oct; 76(10):1267, 1269-70, 1272. PubMed ID: 15902390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?
    Brenner SR; Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2008 Aug; 71(8):615; author reply 615-6. PubMed ID: 18711118
    [No Abstract]   [Full Text] [Related]  

  • 19. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 20. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
    Hernandez-Perez MA;
    Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.